View Post

The FDA’s Oncology Center of Excellence — Quantifying the Patient Experience

In In The News by Barbara Jacoby

By: Paul G. Kluetz, M.D. From: Cancer therapies are typically evaluated based on their ability to control the growth of a tumor or extend life. Tumor response and survival data are strong trial endpoints that remain the mainstay of regulatory review, but cancer patients have other meaningful concerns as well, such as coping with treatment-related side effects that can …